OBJECTIVES: Tedizolid is a novel oxazolidinone for the treatment of complicated skin and soft tissue infections (cSSTIs) including those caused by methicillin-resistant Staphylococcus aureus(MRSA). We aimed to estimate budget impact following the introduction of tedizolid for the treatment of suspected or documented MRSA cSSTIs in a Russian multi-field hospital.

METHODS: Budget impact model of MRSA cSSTIs management was built based on the results of network meta-analyses (R. McCool et al., 2015; J.F. Logman et al., 2010), randomized controlled trials, observational studies and experts’ opinion. Tedizolid introduction as linezolid replacement in a simulated cohort of 100 inpatients with suspected or documented MRSA cSSTIs was assessed for 1 year time horizon. Treatment durations for tedizolid and linezolid were modelled at 6 and 10 days, respectively, consistent with drug labels and meta-analyses data. Direct and opportunity medical costs were considered. Need for second-line treatment courses, de-escalation therapy and gram-negative coverage was accounted for each regimen. Unit costs were extracted from official sources. Univariate sensitivity analysis was conducted on key model parameters.

RESULTS: The budget for the treatment of 100 inpatients with suspected or documented MRSA cSSTIs with linezolid and tedizolid was €94578 and €55230 respectively, including €61265 and €60538 of medications costs respectively. Replacement of linezolid with tedizolid will result in €39348 total budget savings (including €727 savings on drugs) and hospital bed usage optimisation by 31.6%. Results were sensitive to change in linezolid and tedizolid treatment courses duration and costs and to the amount of cSSTI management reimbursement. Tedizolid introduction becomes cost-ineffective for treatment courses ≥9 days long. Uncertainty of other parameters within reasonable limits had no impact on the results.

CONCLUSIONS: Tedizolid is a cost saving alternative to linezolid for the treatment of suspected or documented MRSA cSSTIs in a Russian multi-field hospital.